LPCN Lipocine Inc.

3.99
+0.28  (8%)
Previous Close 3.71
Open 3.89
Price To book 3.27
Market Cap 82483307
Shares 20,672,508
Volume 716,304
Short Ratio 10.64
Av. Daily Volume 182,828

SEC filingsSee all SEC filings

  1. 8-K - Current report 171141764
  2. S-3 - Registration statement under Securities Act of 1933 171136658
  3. 8-K - Current report 171098646
  4. 8-K - Current report 171095097
  5. 8-K - Current report 171093293

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released September 2016. End of Phase 2 meeting with FDA planned.
LPCN 1111
Oral testosterone product
CRL issued June 2016. NDA resubmitted with new PDUFA February 8, 2017. Advisory Committee meeting January 10, 2018.
LPCN 1021
Men with low testosterone (Low T)
Phase 3 protocol filed with FDA 2Q 2017.
LPCN 1107
Prevention of preterm birth ("PTB").

SEC Filings

  1. 8-K - Current report 171141764
  2. S-3 - Registration statement under Securities Act of 1933 171136658
  3. 8-K - Current report 171098646
  4. 8-K - Current report 171095097
  5. 8-K - Current report 171093293
  6. 8-K - Current report 171077063
  7. 8-K - Current report 171027247
  8. 8-K - Current report 171016481
  9. 8-K - Current report 171013272
  10. 8-K - Current report 171010103